Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CB-103 by Cellestia Biotech for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
CB-103 is under clinical development by Cellestia Biotech and currently in Phase II for Adenoid Cystic Carcinoma (ACC). According to...